Press Releases InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline June 3, 2015 Read More » InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) May 26, 2015 Read More » InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases May 12, 2015 Read More » InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750 May 7, 2015 Read More » InMed Engages Peter Mountford as Strategic Advisor May 5, 2015 Read More » InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S. April 30, 2015 Read More » InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy April 15, 2015 Read More » InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000 April 6, 2015 Read More » InMed Pharmaceuticals Strengthens Scientific Advisory Board March 31, 2015 Read More » InMed Receives Exemption Status from Health Canada March 23, 2015 Read More » InMed Pharmaceuticals added to CSE Composite Index March 20, 2015 Read More » InMed Initiates Pre-clinical Work on Orofacial Pain March 18, 2015 Read More » InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies March 10, 2015 Read More » InMed Pharmaceuticals Appoints Dr. Ado Mohammed as Chief Medical Officer March 4, 2015 Read More » InMed Pharmaceuticals to Present Live Investor Webcast March 5, 2015 March 2, 2015 Read More » InMed Expands Board of Directors with Senior Life Science and Financial Executives Appoints Tarek S. Mansour, Ph.D., and Kevin Puil to Board of Directors March 2, 2015 Read More » InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for up to C$1,050,000 February 25, 2015 Read More » InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$500,000 February 10, 2015 Read More » InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS) February 3, 2015 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline June 3, 2015 Read More »
InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) May 26, 2015 Read More »
InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases May 12, 2015 Read More »
InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750 May 7, 2015 Read More »
InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy April 15, 2015 Read More »
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000 April 6, 2015 Read More »
InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies March 10, 2015 Read More »
InMed Expands Board of Directors with Senior Life Science and Financial Executives Appoints Tarek S. Mansour, Ph.D., and Kevin Puil to Board of Directors March 2, 2015 Read More »
InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for up to C$1,050,000 February 25, 2015 Read More »
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$500,000 February 10, 2015 Read More »
InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS) February 3, 2015 Read More »
